

Supplementary

Table S1 The baseline clinical information and CMR, TTE of TAK patients with follow-up and with lost follow-up

	Patients with follow-up (n=30)	Patients with lost follow-up (n=21)	Statistical parameters	P
Clinical characteristics(n=51)				
Female	19 (63.33%)	14 (66.66%)	0.06	0.81*
Age (years)	36±12	41±12	-1.46	0.15**
BMI (kg/m ²)	21.89±3.67	24.30 ±3.06	2.46	0.017**
Heart rate (beats/min)	71±12	73±14	0.294	0.77**
Disease duration (months)	10 (1-432)	24 (1-240)	-1.81	0.07 [§]
Active disease at admission time (NIH criteria)	18 (60%)	10 (47.62%)	0.77	0.38*
Cardiovascular complications (n=47)				
HTN	6 (27, 22.22%)	4 (20, 19.05%)		>0.99 ^{§&}
PH	7 (27, 25.93%)	5 (20, 23.81%)	0.005	0.943*
ESR (mm/h)	13 (2-96)	9 (2-36)	-0.71	0.48&
CMR(n=51)				
LVEF (%)	0.61 ± 0.06	0.64 ± 0.07	-1.62	0.11**
LVEDVI (mL/m ²)	45.96 ± 9.78	49.74 ± 11.68	1.25	0.217**
LVESVI (mL/m ²)	17.94 ± 5.77	17.22 ± 4.86	-0.47	0.640**
CI (L/min/m ²)	3.30 ± 0.69	3.67 ± 1.02	1.54	0.130**
Diastolic myocardiac mass index(g/m ²)	26.33 ± 8.14	28.39 ± 6.03	0.983	0.331**
LGE on CMR	16 (53.33%)	8 (38.10%)	5.28	0.26*
LVEF on TTE	0.69 ± 0.06	0.67 ± 0.08	0.62	0.53**

Notes: CI, cardiac output index; CMR, cardiac magnetic resonance imaging; EDVI, end-diastolic volume index; EF, ejection fraction; ESVI, end-systolic volume index; ESR, erythrocyte sedimentation rate; HTN, hypertension; LGE, late gadolinium enhancement; LV, left ventricular; PH, pulmonary hypertension; TAK, Takayasu's arteritis; TTE, transthoracic echocardiography. Data with skewed distribution represented by median, maximum and minimum values. Four patients with PH and HTN were excluded in cardiovascular complications analysis. *, χ^2 test; **, t-test; [§], Mann-Whitney U test; ^{§&}, Fisher's exact test.